Table 3 Comparison of clinical data between the growth-hormone (GH)-treated and control groups
|  | GH (n = 107) | Control (n = 51) | P-value | RR (95% CI) |
|---|---|---|---|---|
Implantation rate (%) | 63/175 (36.00%) | 15/84 (17.86%) | 0.005 | 2.016 (1.224–3.322) |
Clinical pregnancy rate/cycle start (%) | 47/107 (43.93%) | 10/51 (19.61%) | 0.005 | 2.240 (1.235–4.064) |
Clinical pregnancy rate/ET (%) | 47/91 (51.65%) | 10/45 (22.22%) | 0.002 | 2.324 (1.299–4.158) |
Early miscarriage rate/cycle start (%) | 3/107 (2.80%) | 1/51 (2.00%) | 1 | Â |
Early miscarriage rate//ET (%) | 3/91 (3.30%) | 1/45 (2.22%) | 1 | Â |
Fresh ET rate (%) | 69/91 (75.82%) | 37/45 (82.22%) | 0.531 | Â |
Fresh ET clinical pregnancy rate (%) | 37/69 (53.62%) | 8/37 (21.62%) | 0.003 | 2.480 (1.293–4.758) |
Fresh ET ongoing pregnancy rate (%) | 34/69 (49.28%) | 7/37 (18.92%) | 0.004 | Â |
Fresh ET live birth rate (%) | 34/69 (49.28%) | 7/37 (18.92%) | 0.004 | 2.605 (1.282–5.291) |
Frozen ET rate(%) | 22/91 (24.18%) | 8/45 (17.78%) | 0.531 | Â |
Frozen ET clinical pregnancy rate (%) | 10/22 (45.45%) | 2/8 (25.00%) | 0.555 | Â |
Frozen ET ongoing pregnancy rate (%) | 10/22 (45.45%) | 2/8 (25.00%) | 0.555 | Â |
Frozen ET live birth rate (%) | 10/22 (45.45%) | 2/8 (25.00%) | 0.555 | 1.818 (0.503–6.569) |
Ongoing pregnancy rate /cycle start (%) | 44/107 (41.12%) | 9/51 (17.65%) | 0.006 | Â |
Ongoing pregnancy rate /ET (%) | 44/91 (48.35%) | 9/45 (20.00%) | 0.003 | Â |
Live birth rate/cycle start (%) | 44/107 (41.12%) | 9/51 (17.65%) | 0.006 | 2.330 (1.235–4.396) |
Live birth rate/ET (%) | 44/91 (48.35%) | 9/45 (20.00%) | 0.003 | 2.418 (1.298–4.502) |